<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315444</url>
  </required_header>
  <id_info>
    <org_study_id>AT 101</org_study_id>
    <secondary_id>RMC 101</secondary_id>
    <nct_id>NCT01315444</nct_id>
  </id_info>
  <brief_title>Gastric Acid Rebound Secretion Measured by Alkaline Tide</brief_title>
  <official_title>Gradual Cessation of Proton Pump Inhibitor (PPI) Treatment May Prevent Rebound Acid Secretion in Dyspeptic and Reflux Patients, Measured by the Alkaline Tide Method.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastro esophageal reflux disease and ulcer related or non-ulcer dyspepsia, attacks 20% of the&#xD;
      Western population. These millions of patients are treated continuously with PPI for&#xD;
      different periods, many for many years. Recently, rebound acid hypersecretion was recognized&#xD;
      as a major clinical event after cessation of PPI therapy. Sustained hypergastrinemia due to&#xD;
      daily PPI therapy causes increased acid-secretory capacity that appears when the drug is&#xD;
      stopped. The transient increase in blood and urinary pH following gastric secretion has been&#xD;
      termed the alkaline tide phenomenon. Carbonic acid, formed in the presence of the enzyme&#xD;
      carbonic anhydrase, neutralizes intracellular hydroxyl ions produced as a result of luminal&#xD;
      acid secretion. The bicarbonate generated is removed from the cell via the baso-lateral&#xD;
      chloride bicarbonate exchanger. The investigators have shown in several studies that this&#xD;
      phenomenon parallels acid secretion. Thus, stimulation of acid secretion with test meal&#xD;
      increased base excess maximally after 45 minutes and these changes parallel peak acid output&#xD;
      measured in gastric aspirate. The investigators hypothesize that gradual step down cessation&#xD;
      of PPI will prevent this clinical relevant event. By measuring alkaline tide after PPI&#xD;
      cessation the investigators may prove this hypothesis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prevention of acid rebound phenomenon after stoping PPI</measure>
    <time_frame>30 days</time_frame>
    <description>Comparing gradual and abrupt PPI cesation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Condition Measuring Alkaline Tide and Filling Symptoms' Questionnaire After Abrupt or Gradual Step Down Cessation of PPI</condition>
  <arm_group>
    <arm_group_label>PPI abrupt cessation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abrupt cessation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPI gradual step down cessation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gradual cessation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stop PPI gradually</intervention_name>
    <arm_group_label>PPI abrupt cessation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stop PPI gradually</intervention_name>
    <arm_group_label>PPI gradual step down cessation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dyspepsia and reflux patients older than 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients on PPI, patients with severe diseases, younger than 18 y, older than 80 y,&#xD;
             un-cooperative, COPD, uncompensated IHD, CRF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 13, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel Aviv University</investigator_affiliation>
    <investigator_full_name>Yaron Niv</investigator_full_name>
    <investigator_title>Director, Department of Gastroenterology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

